Ascendis Pharma (ASND) Company Description: Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a ...

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

AstraZeneca has added a late-stage rare disease therapy to its pipeline, buying France ... some hypoparathyroidism patients and, while Ascendis Pharma’s TransCon PTH (palopegteriparatide ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...

DelveInsight's NK cell therapy pipeline report depicts a robust space ... Key NK cell therapy companies such as Amgen, Innate Pharma, Nektar Therapeutics, SMT bio Co., Ltd., Alphageneron ...

Athira Pharma, Inc. (ATHA) has disclosed a new risk, in the Regulation category. Athira Pharma, Inc. faces significant business risk due to its dependency on compliance with FDA regulations for ...

Ascendis Pharma (ASND) is scheduled to announce Q3 earnings results on Thursday, November 14th, after market close. The ...

COPENHAGEN - Ascendis Pharma A/S (NASDAQ:ASND) has reported encouraging outcomes from its ongoing Phase 1/2 IL-Believe Trial, evaluating TransCon IL-2 β/γ therapy for ...

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist. The Danish pharma ...